- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials at Nuvation Bio
- Número de teléfono: 332-208-6102
- Correo electrónico: ClinicalTrials@nuvationbio.com
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Aún no reclutando
- University of California, Los Angeles
-
Investigador principal:
- Robert Chong, MD
-
Contacto:
- Quan Li
- Número de teléfono: 310-825-1416
- Correo electrónico: quanli@mednet.ucla.edu
-
San Francisco, California, Estados Unidos, 94143
- Aún no reclutando
- University of California, San Francisco
-
Investigador principal:
- John De Groot, MD
-
Contacto:
- Neuro Onc New Patient Coordinator
- Número de teléfono: 415-353-2193
- Correo electrónico: neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Aún no reclutando
- Yale University
-
Investigador principal:
- Nicholas Blondin, MD
-
Contacto:
- Amy Rodrigues
- Correo electrónico: amy.rodrigues@yale.edu
-
Contacto:
- Correo electrónico: cto-neuro@yale.edu
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Aún no reclutando
- University of Miami Health
-
Contacto:
- Leonela Wright
- Número de teléfono: 305-243-0864
- Correo electrónico: lxw612@med.miami.edu
-
Investigador principal:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Aún no reclutando
- Indiana University
-
Investigador principal:
- Kathryn Nevel, MD
-
Contacto:
- NeuroOncology Clinical Trials
- Número de teléfono: 3179634823
- Correo electrónico: neuroct@iu.edu
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Aún no reclutando
- LSU LCMC Health Cancer Center
-
Investigador principal:
- Yazmin Odia, MD
-
Contacto:
- Yazmin Odia
- Número de teléfono: (646) 634-9655
- Correo electrónico: yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02214
- Aún no reclutando
- Massachusetts General Hospital
-
Contacto:
- Vihang Nakhate
- Número de teléfono: 617-724-8770
- Correo electrónico: vnakhate@mgh.harvard.edu
-
Investigador principal:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Aún no reclutando
- Rutgers Cancer Institute
-
Investigador principal:
- Morana Vojnic, MD
-
Contacto:
- Kasie Diorio
- Número de teléfono: 732-235-2465
- Correo electrónico: kassie.diorio@rutgers.edu
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Health
-
Contacto:
- Jose McFaline-Figueroa, MD
- Número de teléfono: 212-731-6267
- Correo electrónico: Jose.McFalineFigueroa@nyulangone.org
-
New York, New York, Estados Unidos, 10032
- Aún no reclutando
- Columbia University Medical Center
-
Investigador principal:
- Andrew Lassman, MD
-
Contacto:
- Research Nurse Navigator
- Número de teléfono: 212-342-5162
- Correo electrónico: Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Aún no reclutando
- Cleveland Clinic
-
Investigador principal:
- Mina Lobbous, MD
-
Contacto:
- Marci Ciolfi
- Número de teléfono: 216-445-3307
- Correo electrónico: ciolfim@ccf.org
-
Columbus, Ohio, Estados Unidos, 43210
- Aún no reclutando
- The Ohio State University Comprehensive Cancer Center
-
Contacto:
- Pierre Giglio
- Número de teléfono: 614-293-4448
- Correo electrónico: Pierre.Giglio@osumc.edu
-
Investigador principal:
- Pierre Giglio, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
Periodo de tiempo: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
Periodo de tiempo: From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
Periodo de tiempo: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
Periodo de tiempo: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
Periodo de tiempo: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
Periodo de tiempo: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
Periodo de tiempo: From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
Periodo de tiempo: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
Periodo de tiempo: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NUV-218-G209
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .